Hainan Huluwa Pharmaceutical Group Co Ltd (605199) — Cash Flow-to-Debt Ratio
Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2025, meaning its operating cash flow of CN¥44.34 Million could theoretically repay 0% of its total liabilities (CN¥2.06 Billion) in one year. Check 605199 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hainan Huluwa Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Hainan Huluwa Pharmaceutical Group Co Ltd across 10 annual periods. Also explore Hainan Huluwa Pharmaceutical Group Co Lt total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)
Year-by-year debt coverage analysis for Hainan Huluwa Pharmaceutical Group Co Ltd. For market capitalisation and broader financial context, see how much is Hainan Huluwa Pharmaceutical Group Co Lt worth.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | CN¥136.85 Million | CN¥2.14 Billion | ▲ +195.0% |
| 2024 | -0.07x | CN¥-149.12 Million | CN¥2.22 Billion | ▼ -551.7% |
| 2023 | 0.01x | CN¥28.25 Million | CN¥1.90 Billion | ▼ -91.9% |
| 2022 | 0.18x | CN¥238.71 Million | CN¥1.30 Billion | ▲ +49.2% |
| 2021 | 0.12x | CN¥102.48 Million | CN¥830.41 Million | ▲ +2161.5% |
| 2020 | 0.01x | CN¥3.30 Million | CN¥604.68 Million | ▼ -98.3% |
| 2019 | 0.33x | CN¥144.51 Million | CN¥442.67 Million | ▲ +400.4% |
| 2018 | 0.07x | CN¥31.80 Million | CN¥487.37 Million | ▼ -66.9% |
| 2017 | 0.20x | CN¥89.96 Million | CN¥455.83 Million | ▲ +23.7% |
| 2016 | 0.16x | CN¥64.96 Million | CN¥407.26 Million | — |